Conference Track

Highlight on Special Hepatic Issues and Populations

Source: CCO Independent Conference Coverage of the 2006 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

HAART Duration Not Associated With Fibrosis Severity or Rate of Progression in HIV/HCV-Coinfected Individuals
HIV/HCV-Coinfected Individuals Positive for Hepatitis G Virus Experience Reduced Severity of HCV-Related Liver Disease
Peginterferon Alfa-2a Plus High-Dose Weight-Based Ribavirin and Extended Therapy Duration Results in Higher Rates of SVR and Early Treatment Discontinuation in HIV/HCV-Coinfected Patients
Promising Survival Outcomes for HBV-Infected Individuals With Virologic Failure or Genotypic Resistance While Awaiting OLT if HBV Rescue Therapy Initiated
Interim Analysis: Peginterferon/Ribavirin With or Without Ribavirin Maintenance Yields High Rates of Virologic Suppression in Individuals With HCV Recurrence Following OLT
Noninvasive Measurement of Liver Fibrosis Biomarkers Can Accurately Detect Significant Liver Fibrosis in HIV/HCV-Coinfected Patients
Treatment With Cyclosporine or Tacrolimus Results in Equally Favorable Clinical Outcomes in Liver Transplant Patients Infected With HCV
Higher Incidence of Liver Transplant Complications Among Living Donor Recipients Compared With Deceased Donor Recipients
High Survival Rates in Patients Undergoing Down-Staging of HCC to Receive OLT
Survival Outcomes Poor for HCC Patients, Regardless of HIV Status
Steroid-Free Immunosuppression Effective in Reducing Risk of Rejection Following Liver Transplantation in Hepatitis C Patients
Rapamycin Prolongs Survival After Liver Transplantation for Hepatocellular Carcinoma
HIV Coinfection Lowers Survival and Increases Recurrence of HCV Infection Following Liver Transplantation
DEBIO-025 Produces Significant Reduction in HCV and HIV-1 RNA Levels in HIV/HCV-Coinfected Individuals
HCV/HIV-Coinfected Patients With High IL-6 Expression Experience Improved Response to Interferon Treatment

Expert Analysis

Highlight on Special Hepatic Issues and Populations

Faculty:
Raymond T. Chung, MD Mark S. Sulkowski, MD Norah Terrault, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss results of studies evaluating prognostic factors in patients with liver disease
Review the efficacy of various noninvasive markers of fibrosis in patients with HCV/HIV coinfection
Describe clinical data regarding treatment of patients with HCV/HIV coinfection
Review the latest clinical data on treatment strategies in the setting of liver transplantation
Review data on the use of hepatocellular downstaging in patients awaiting liver transplantation

CME CREDIT INFORMATION

Release Date: 12/13/06

Expiration Date: 12/12/07

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.2 contact hours (0.12 CEUs)

Registered Nurses: 1.4 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.